NCT05269329已完成2 期
Double-blind Placebo-controlled Multicenter Randomized Clinical Trial to Assess Efficacy and Safety of HC8, Film-coated Tablets, 10 mg (Valenta Pharm, Russia) in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 160
- 试验地点
- 9
- 主要终点
- Coughing frequency
研究概览
简要总结
Study to assess the efficacy and safety of XC8, film-coated tablets, 10 mg in comparison with placebo in patients with dry non-productive cough against acute respiratory infections, and to determine the dosing regimen of XC8, film-coated tablets, 10 mg for treatment of dry non-productive cough against acute respiratory infections.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signing and dating of the IPP informed consent form by the patient.
- •Women and men between the ages of 18 and 65 years, inclusive, at the time of signing the informed consent form.
- •Clinical diagnosis of acute respiratory viral infection of the upper respiratory tract (ICD-10 code J00-J06) or acute bronchitis (J20, J21 according to ICD-10).
- •Onset of disease symptoms no more than 3 days prior to screening.
- •Presence of a patient with a dry unproductive cough.
- •Frequency of cough episodes ≥10 in the past 24 h before the screening visit and randomization.
- •Cough frequency rated by the patient as 3-4 on the daytime cough section and 2-4 on the nighttime cough section of the Daytime and Nighttime Cough Scales.
- •Patient rating of cough severity on the DRS ≥ 4 points.
- •No indication for therapy due to BHSA infection at the time of study inclusion: negative rapid test for Group A β-haemolytic streptococcus.
- •For women of preserved reproductive potential, a negative pregnancy test and agreement to use approved contraceptive methods for the duration of study participation, beginning at visit 0, and for 3 weeks after the end of the study; for men, agreement to use approved contraceptive methods throughout the study participation period and for 3 weeks after the end of the study.
排除标准
- •Known or suspected hypersensitivity to the active ingredient or any of the excipients of the study drug/placebo.
- •Known or suspected hypersensitivity to acetylcysteine.
- •Lactose intolerance, lactase deficiency, glucose-galactose malabsorption.
- •Trauma (including open wounds in the mouth and erosive-desquamous lesions of the oral mucosa) and/or oropharyngeal burns, scarlet fever, rubella, measles, mumps at the time of screening or within 3 months prior to screening.
- •Acute obstructive laryngitis or suspected obstructive laryngitis.
- •Presence of signs of laryngeal stenosis (stridor, shortness of breath).
- •Exacerbation of chronic bronchitis or chronic obstructive pulmonary disease (COPD).
- •Bronchial asthma, including a history.
- •History of tuberculosis.
- •History of pulmonary emphysema.
- •Acute or chronic pneumonia, or suspected pneumonia.
- •Condition after intubation.
- •Gastroesophageal reflux being the primary cause of cough (as judged by the investigating physician).
- •Allergic rhinitis as primary cause of cough (according to study physician).
- •Body temperature > 39.0 °C.
- •Presence of at least one of the epidemic signs: return from a foreign trip 14 days prior to the onset of symptoms; presence of close contact in the past 14 days with a person under COVID-19 surveillance who has subsequently become ill; having close contact in the past 14 days with a person who has a laboratory-confirmed diagnosis of COVID-19; having occupational contacts with an individual with a suspected or confirmed case of COVID-
- •Positive result of laboratory testing for SARS-CoV-2 RNA using nucleic acid amplification techniques or SARS-CoV-2 antigen using immunochromatographic analysis at the time of screening.
- •The need for systemic antibiotic therapy and/or other drugs/procedures from the list of prohibited therapies/procedures.
- •Use of analgesics or antipyretics within 12 hours prior to screening.
- •Use of glucocorticosteroids, β-adrenoblockers, ACE inhibitors, theophylline drugs, expectorants, cough suppressants, anesthetics, anti-allergic drugs (leukotriene receptor antagonists, H1-histamine receptor blockers, sodium cromoglycate preparations), antiviral drugs, immunosuppressants, systemic antibacterial drugs for 7 days before screening.
- •History of smoking more than 10 pack/years (pack-years: number of cigarettes smoked per day multiplied by the number of years of smoking divided by 20).
- •Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) levels ≥ 2.5 × highest normal value, serum bilirubin levels ≥ 1.5 × highest normal value.
- •Glomerular filtration rate (GFR) ≤ 60 ml/min.
- •History of cancer of the respiratory system.
- •History of other malignancies, except for patients who have not had the disease in the past 5 years, patients with fully cured basal cell carcinoma of the skin, or fully cured carcinoma in situ.
- •Serious cardiovascular disease at the time of screening or within 12 months prior to screening, including: New York Heart Association Class III or IV chronic heart failure, severe arrhythmias requiring treatment with antiarrhythmic drugs, unstable angina pectoris, myocardial infarction, heart and coronary artery surgery, transient ischemic attack or stroke, uncontrolled hypertension with systolic blood pressure > 180 mm Hg Std. and diastolic blood pressure >110 mmHg, pulmonary embolism.
- •Other severe, decompensated or unstable somatic diseases (any disease or condition that threatens the patient's life or worsens the patient's prognosis, or makes it impossible for the patient to participate in a clinical trial).
- •Patient's unwillingness or inability to comply with protocol procedures (in the opinion of the research physician).
- •Pregnancy or breastfeeding (for women).
- •Alcoholism, drug dependence, substance abuse history and/or at the time of screening.
- •A history of schizophrenia, schizoaffective disorder, bipolar disorder or other psychiatric pathology.
- •Participation in another clinical trial within 3 months prior to inclusion in the study.
- •Other conditions that, in the opinion of the investigating physician, preclude inclusion of the patient in the study.
- •Withdrawal Criteria:
- •Identification of a probable or confirmed case of COVID-19
- •Ineffectiveness of therapy - persistence or increased frequency of cough attacks ≥ 1 by visit 3 (day 8-9) compared to visit 1 (day 1).
- •AEs requiring withdrawal of study drug/placebo.
- •The occurrence of any disease or condition during the study that, in the opinion of the study physician, worsens the patient's prognosis and also makes it impossible for the patient to continue participating in the clinical trial.
- •Erroneous inclusion of a patient who does not meet the inclusion criteria and/or meets the inclusion criteria.
- •Taking any of the drugs of prohibited therapy, performing a prohibited procedure.
- •The necessity of prescribing prohibited concomitant therapy/procedures.
- •Pregnancy of the patient.
- •Patient's desire to stop participating in the study.
- •Lack of adequate cooperation of the patient with the doctor-researcher during the study.
- •Other protocol violations that are significant in the opinion of the physician-researcher.
- •Other administrative reasons.
研究组 & 干预措施
XC8, film-coated tablets, 20 mg/day
Experimental
干预措施: XC8, film-coated tablets, 20 mg/day (Drug)
XC8, film-coated tablets, 40 mg/day
Experimental
干预措施: XC8, film-coated tablets, 40 mg/day (Drug)
XC8, film-coated tablets, 80 mg/day
Experimental
干预措施: XC8, film-coated tablets, 80 mg/day (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Coughing frequency
时间窗: The estimate will include data from 24 hours to Day 1 and Day 5
Change in coughing frequency by ≥ -50% by day 5 relative to visit 1
次要结局
- Frequency of cough episodes(The assessment will include data for 24 h before days 5, 8, 11, and 15, respectively.)
- Percentage of patients with ≥1 point decrease in daytime cough(Assessment will include data for days 4, 7, 10, and 14, respectively.)
- Change in each symptom score(Assessment will include data for days 4, 7, 10, and 14, respectively.)
- Proportion of patients with "very high" and "high" efficacy(From Day 3-4 (visit 2) up to Day 16 (visit 5).)
- Safety - Adverse Events (AEs)(From visit 0 up to Day 20 +/- 2 (visit 6).)
- Safety - Percentage of patients with at least one AE(From visit 0 up to Day 20 +/- 2 (visit 6).)
- Time to clinical cough cure(From Day 1 (visit 1) to the first day of consecutive days on which ≤ 1 point on the Daytime Cough and Nighttime Cough Scales sections of the Daytime and Nighttime Cough Scales is recorded, assessed up to Day 16 (visit 5).)
- Time (days) from visit 1 to a reduction in cough severity(From Day 1 (visit 1) up to Day 16 (visit 5).)
- Time (days) from visit 1 to administration of acetylcysteine(From Day 1 (visit 1) up to Day 16 (visit 5).)
- Proportion of patients dropped out of the study due to prescription of systemic antibiotic therapy.(From Day 1 (visit 1) up to Day 16 (visit 5).)
- Percentage of patients with ≥1 point decrease in nighttime cough(Assessment will include data for the night before days 5, 8, 11, and 15, respectively.)
- Safety - Percentage of patients who interrupted the treatment due to AE(From visit 0 up to Day 20 +/- 2 (visit 6).)
- Proportion of patients with ≤ 1 score on the daytime cough and nighttime cough Scales sections(The daytime cough section score will include data for days 4, 7, 10, and 14, respectively. The nighttime cough section score will include data for the night preceding days 5, 8, 11, and 15, respectively.)
- Percentage of patients with a reduction of ≥ 2 points in the nighttime cough(Assessment will include data for the night before days 5, 8, 11, and 15, respectively.)
- Percentage of patients prescribed acetylcysteine(From Day 1 (visit 1) up to Day 16 (visit 5).)
- Time (days) from visit 1 to achieving ≤ 1 score on the daytime cough(From Day 1 (visit 1) up to Day 16 (visit 5).)
- Proportion of patients with a score ≤ 1 on the daytime cough(Assessment will include data for days 4, 7, 10, and 14, respectively.)
- Change (score) in the nighttime cough(Assessment will include data for the night before days 5, 8, 11, and 15, respectively.)
- Percentage of patients with a decrease of ≥1 score on each symptom(Assessment will include data for days 4, 7, 10, and 14, respectively.)
- Safety - Adverse Reactions(From visit 0 up to Day 20 +/- 2 (visit 6).)
- Proportion of patients with attainment of ≤ 1 point on each symptom(Assessment will include data for days 4, 7, 10, and 14, respectively.)
- Change (score) in cough severity(The score will include data 24 h before days 5, 8, 11, and 15, respectively.)
- Change (score) in daytime cough(Assessment will include data for days 4, 7, 10, and 14, respectively.)
- Proportion of patients with ≥ 2 points reduction in daytime cough(Assessment will include data for days 4, 7, 10, and 14, respectively.)
- Time (days) from visit 1 to reaching ≤ 1 score on the nighttime cough(From Day 1 (visit 1) up to Day 16 (visit 5).)
- Proportion of patients with a score ≤ 1 on nighttime cough(Assessment will include data for the night before days 5, 8, 11, and 15, respectively.)
- Proportion of patients with body temperature ≤ 37.0 °C(From Day 3-4 (visit 2) up to Day 16 (visit 5).)
- Change in the number of episodes of nocturnal awakening due to cough(Assessment will include data for the night before days 5, 8, 11, and 15, respectively.)
- Time (days) to attain ≤ 1 score for each symptom(From Day 1 (visit 1) up to Day 16 (visit 5).)
- Percentage of patients with complete resolution of all symptoms(Assessment will include data for days 4, 7, 10, and 14, respectively.)
- Proportion of patients with each category of Global Assessment scale(From Day 3-4 (visit 2) up to Day 16 (visit 5).)
- Safety - Serious adverse events (SAEs)(From visit 0 up to Day 20 +/- 2 (visit 6).)
研究者
研究点 (9)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral InfectionInfluenza, HumanCommon ColdAcute Respiratory InfectionNCT05273619Valenta Pharm JSC250
招募中
3 期
Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral InfectionsAcute Respiratory InfectionNCT06379542Valenta Pharm JSC252
已完成
1 期
Study to Assess Pharmacokinetics, Safety, and Tolerability of XC-8AsthmaNCT02882217EURRUS Biotech GmbH32
已完成
2 期
Study To Evaluate Efficacy And Safety Of An Additional Dose Of Celecoxib (YM177) In Patients With Post-Tooth Extraction PainPainNCT01062113Pfizer's Upjohn has merged with Mylan to form Viatris Inc.255
已完成
2 期
Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)SchizophreniaNCT00848484Merck Sharp & Dohme LLC54